Replies to post #224682 on Biotech Values

[semi_infinite]

Remind me of the decreases in viral load, in log scale, of the HCV nuc's that were cleared by FDA in currently available combos.

[DewDiligence]

(ASMB)—ENTA’s CEO, Jay Luly just said that ASMB’s HBV core inhibitor is probably too weak, based on data presented at EASL (in so many words).